Rivaroxaban, colchicine, and famotidine-loratadine with specialist care for post-COVID fatigue: a UK randomized trial on safety and effectiveness

Declaration of interests ECW participated in the Data Safety and Monitoring Board for the RECLAIM trial. RAE received payments from the UK Covid Inquiry and Scottish Covid Inquiry; a grant from Genentec/Roche; and speaker fees from BMJ Best Practice and Moderna; and was Chair of the European Respiratory Society Group 01.02 Pulmonary Rehabilitation and Chronic Care (2023–26), Chair of the American Thoracic Society Pulmonary Rehabilitation Assembly (2022–25), and a member of the ATS Pulmonary Rehabilitation Assembly Nominating Committee (2025–27). All other authors declare no competing interests.